Skip to main content
Maria Palomba, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

MariaLiaPalombaMD

Oncology • New York, NY

Hematologic Oncology

Professor, Medicine, Weill Cornell Medical College

Request Appointment

Overview of Dr. Palomba

Dr. Maria Palomba is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from University of Pavia Faculty of Medicine and has been in practice 30 years. Dr. Palomba accepts several types of health insurance, listed below. She is one of 464 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Italian. She has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Mount Auburn Hospital
    Mount Auburn HospitalResidency, Internal Medicine, 1997 - 1999
  • University of Pavia Faculty of Medicine
    University of Pavia Faculty of MedicineClass of 1987

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 2002 - 2025
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • CT State Medical License
    CT State Medical License 2023 - 2024
  • NC State Medical License
    NC State Medical License 2020 - 2022

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia  
    Jeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine

Abstracts/Posters

  • Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
    Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
    Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
    Maria Lia Palomba, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Fast and Furious Cars: Looking Ahead to Next-Generation Treatments and New Combinations 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL “Armored” CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Tr... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Professional Memberships

Other Languages

  • Italian

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Medical Mutual of Ohio SuperMed Plus
    Medical Mutual of Ohio SuperMed POS
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Maria Palomba, Dr. Maria Palomba, MD, Dr. M Palomba, Dr. Maria Lia Palomba